Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$217.21 USD
-0.34 (-0.16%)
Updated May 24, 2024 04:00 PM ET
After-Market: $217.18 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Brokerage Reports
Charles River Laboratories International, Inc. [CRL]
Reports for Purchase
Showing records 361 - 380 ( 381 total )
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
The Bull Market Rages On (Society of Toxicology Recap)
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Equity Research: Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Society of Toxicology Meeting Confirms Investor Optimism for Preclinical
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Positive Read from Covance Early Development Strength
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Soft 1Q14 to Put Charles River in Catch-Up Mode for Rest of 2014
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
Initiation of Coverage of Biopharmaceutical Services
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D
Company: Charles River Laboratories International, Inc.
Industry: Medical Services
We are initiating coverage with a HOLD rating with the stock trading at ~11.4x our 2015 EBITDA estimate of ~$317 million (consensus: $311 million)
Provider: KEYBANC CAPITAL MARKETS
Analyst: HOOKER D